Overview

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Xiamen University

Collaborators:

Chipscreen Biosciences, Ltd.
CSPC Pharmaceutical Group Limited
Fujian Cancer Hospital
Fujian Provincial Hospital
Huizhou Municipal Central Hospital
Jieyang People's Hospital
Zhangzhou manicipal hospital of Fujian Province

Treatments:

Azacitidine
Cytarabine
Mitoxantrone
Venetoclax